☆ 4.7 Article

Effectiveness of Coronavirus Disease 2019 (COVID-19) Vaccines Among Incarcerated People in California State Prisons: Retrospective Cohort Study

CLINICAL INFECTIOUS DISEASES (2022)

Related references

Note: Only part of the references are listed.

Letter Medicine, General & Internal

Effectiveness of the mRNA-1273 Vaccine during a SARS-CoV-2 Delta Outbreak in a Prison

Elizabeth T. Chin et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting

Noa Dagan et al.

Summary: A study conducted in Israel on nearly 600,000 individuals showed that the BNT162b2 mRNA vaccine was effective in reducing the risk of infection, hospitalization, and severe Covid-19. The effectiveness in preventing death was 72% during the period from day 14 through day 20 after the first dose, and hospitalization was reduced by 87% for the period 7 or more days after the second dose, similar to results from a randomized trial.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Association Between Vaccination With BNT162b2 and Incidence of Symptomatic and Asymptomatic SARS-CoV-2 Infections Among Health Care Workers

Yoel Angel et al.

Summary: This cohort study in Tel Aviv, Israel, found that vaccination with the Pfizer-BioNTech BNT162b2 vaccine was significantly associated with a lower incidence of symptomatic and asymptomatic SARS-CoV-2 infection among health care workers more than 7 days after the second dose.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

Add to Collection

Article Public, Environmental & Occupational Health

Outbreaks of COVID-19 variants in US prisons: a mathematical modelling analysis of vaccination and reopening policies

Theresa Ryckman et al.

Summary: This study uses mathematical modelling to evaluate the risks and harms of COVID-19 outbreaks in prisons, finding that high vaccination coverage and non-pharmaceutical interventions can significantly reduce infection rates. Even in prisons with low infection rates, the hospitalization risks for medically vulnerable populations remain substantial.

LANCET PUBLIC HEALTH (2021)

Add to Collection

Article Medicine, General & Internal

Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study

Eleftheria Vasileiou et al.

Summary: The study in Scotland found that the first doses of the BNT162b2 mRNA and ChAdOx1 vaccines were associated with substantial reductions in the risk of COVID-19 hospital admission, with vaccine effectiveness ranging from 88% to 91% at 28-34 days post-vaccination.

LANCET (2021)

Add to Collection

Article Medicine, General & Internal

Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data

Eric J. Haas et al.

Summary: This study assessed the real-world effectiveness of the Pfizer-BioNTech mRNA COVID-19 vaccine BNT162b2 in Israel, showing high efficacy in preventing SARS-CoV-2 infections, hospitalizations, severe disease, and death. As vaccine coverage increased, there were marked declines in SARS-CoV-2 outcomes, indicating that COVID-19 vaccination can help control the pandemic.

LANCET (2021)

Add to Collection

Letter Medicine, General & Internal

Covid-19 Vaccine Acceptance in California State Prisons

Elizabeth T. Chin et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Public, Environmental & Occupational Health

Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Among Hospitalized Adults Aged ≥65 Years — United States, January–March 2021

Mark W. Tenforde et al.

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2021)

Add to Collection

Article Public, Environmental & Occupational Health

Effectiveness of the Pfizer-BioNTech COVID-19 Vaccine Among Residents of Two Skilled Nursing Facilities Experiencing COVID-19 Outbreaks - Connecticut, December 2020-February 2021

Amadea Britton et al.

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2021)

Add to Collection

Article Public, Environmental & Occupational Health

COVID-19 Outbreak Associated with a SARS-CoV-2 R.1 Lineage Variant in a Skilled Nursing Facility After Vaccination Program - Kentucky, March 2021

Alyson M. Cavanaugh et al.

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2021)

Add to Collection

Article Health Care Sciences & Services

COVID-19 in the California State Prison System: an Observational Study of Decarceration, Ongoing Risks, and Risk Factors

Elizabeth T. Chin et al.

Summary: The study observed a 19.1% decrease in the incarcerated population in California state prisons during the COVID-19 pandemic. It found that nearly 40% of residents with high COVID-19 risk scores lived in dormitories, where infection rates were higher compared to cell residents. Additionally, residents of rooms with labor participation also had higher infection rates. Further reducing risks in prisons will require a combination of strategies, including rehousing, decarceration, and vaccination.

JOURNAL OF GENERAL INTERNAL MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines

Mark G. Thompson et al.

Summary: The study demonstrated that COVID-19 mRNA vaccines were highly effective in preventing SARS-CoV-2 infection in real-world conditions, while also attenuating the viral RNA load, febrile symptoms, and illness duration among vaccinated individuals who had breakthrough infections.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months

S. J. Thomas et al.

Summary: BNT162b2 vaccine remains highly effective and safe over the course of 6 months post-vaccination, with efficacy rates ranging from 86% to 100% across different demographics and risk factors for Covid-19. The vaccine also shows a high efficacy against severe disease, with particularly promising results observed in South Africa against the B.1.351 variant.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Multidisciplinary Sciences

COVID-19 vaccine prioritization of incarcerated people relative to other vulnerable groups: An analysis of state plans

Rachel Strodel et al.

Summary: In the United States, incarcerated individuals have not been prioritized in COVID-19 vaccine allocation plans, and there is no clear guidance on when they will be eligible for vaccination.

PLOS ONE (2021)

Add to Collection

Article Public, Environmental & Occupational Health

Measurement of Vaccine Direct Effects Under the Test-Negative Design

Joseph A. Lewnard et al.

AMERICAN JOURNAL OF EPIDEMIOLOGY (2018)

Add to Collection

Editorial Material Immunology

Clinical trials: The mathematics of falling vaccine efficacy with rising disease incidence

M. Gabriela M. Gomes et al.

VACCINE (2016)

Add to Collection

Article Medicine, General & Internal

The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies

Erik von Elm et al.

LANCET (2007)

Add to Collection

© Peeref 2019-2024. All rights reserved.